Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tirvalimogene teraplasmid - Genexine

Next Previous
Drug Profile

Tirvalimogene teraplasmid - Genexine

Alternative Names: GX-188; GX-188E; NOV-1702; Papitrol; Papitrol-188; pGX27-E6E7

Latest Information Update: 05 Jul 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genexine
  • Developer Genexine; Merck & Co; Yonsei University
  • Class Antineoplastics; Cancer vaccines; DNA vaccines; Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Cervical intraepithelial neoplasia; Head and neck cancer

Most Recent Events

  • 02 Jun 2023 Updated pharmacodynamics data from a phase II trial in Head and neck cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
  • 26 May 2023 Efficacy and pharmacodynamics data from a phase II trial in Head and neck cancer released by Genexine
  • 20 Jan 2023 Genexine completes a phase I/II trial in Cervical cancer (Late-stage disease, Metastatic disease, Combination therapy, Second-line therapy or greater) in South Korea(IM) (NCT03444376)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top